A retrospective study of clinical characteristics and outcomes of SARS-CoV-2 infection after vaccination in patients with rheumatic diseases
Latest Information Update: 29 Jun 2022
Price :
$35 *
At a glance
- Drugs AZD 1222 (Primary) ; Coronavirus vaccine-Wuhan Institute of Biological Products (Primary) ; COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- 29 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism